###begin article-title 0
Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
###end article-title 0
###begin p 1
###xml 334 342 <span type="species:ncbi:9606">patients</span>
Conceived and designed the experiments: KM RB AG MM NN RS ET JRW MQW DAW AW SEK PHW BN. Performed the experiments: KM RB AG NN AN RS ET JRW MQW DAW AW MK BG. Analyzed the data: KM RB AG MM NN AN JSN RS ET JRW MQW DAW AW MK SEK BG PHW BN. Contributed reagents/materials/analysis tools: EM. Wrote the paper: KM RB JSN PHW BN. Recruited patients to this study: EM.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 356 361 <span type="species:ncbi:9606">human</span>
Tumor-infiltrating CD8+ T cells are correlated with prolonged progression-free and overall survival in epithelial ovarian cancer (EOC). A significant fraction of EOC patients mount autoantibody responses to various tumor antigens, however the relationship between autoantibodies and tumor-infiltrating T cells has not been investigated in EOC or any other human cancer. We hypothesized that autoantibody and T cell responses may be correlated in EOC and directed toward the same antigens.
###end p 3
###begin title 4
Methodology and Principal Findings
###end title 4
###begin p 5
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 864 871 <span type="species:ncbi:9606">patient</span>
We obtained matched serum and tumor tissue from 35 patients with high-grade serous ovarian cancer. Serum samples were assessed by ELISA for autoantibodies to the common tumor antigen NY-ESO-1. Tumor tissue was examined by immunohistochemistry for expression of NY-ESO-1, various T cell markers (CD3, CD4, CD8, CD25, FoxP3, TIA-1 and Granzyme B) and other immunological markers (CD20, MHC class I and MHC class II). Lymphocytic infiltrates varied widely among tumors and included cells positive for CD3, CD8, TIA-1, CD25, FoxP3 and CD4. Twenty-six percent (9/35) of patients demonstrated serum IgG autoantibodies to NY-ESO-1, which were positively correlated with expression of NY-ESO-1 antigen by tumor cells (r = 0.57, p = 0.0004). Autoantibodies to NY-ESO-1 were associated with increased tumor-infiltrating CD8+, CD4+ and FoxP3+ cells. In an individual HLA-A2+ patient with autoantibodies to NY-ESO-1, CD8+ T cells isolated from solid tumor and ascites were reactive to NY-ESO-1 by IFN-gamma ELISPOT and MHC class I pentamer staining.
###end p 5
###begin title 6
Conclusion and Significance
###end title 6
###begin p 7
###xml 99 104 <span type="species:ncbi:9606">human</span>
We demonstrate that tumor-specific autoantibodies and tumor-infiltrating T cells are correlated in human cancer and can be directed against the same target antigen. This implies that autoantibodies may collaborate with tumor-infiltrating T cells to influence clinical outcomes in EOC. Furthermore, serological screening methods may prove useful for identifying clinically relevant T cell antigens for immunotherapy.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 403 406 403 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Bookman1">[1]</xref>
###xml 573 576 573 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Ozols1">[2]</xref>
###xml 578 581 578 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-duBois1">[3]</xref>
###xml 88 93 <span type="species:ncbi:9606">women</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
Epithelial ovarian cancer (EOC) is a challenging disease that affects more than 190,000 women worldwide each year (International Agency for Research on Cancer). The high mortality rate is attributed to the fact that most patients are diagnosed with disseminated disease, often with extensive ascites. Standard treatment involves cytoreductive surgery followed by taxane- and platinum-based chemotherapy [1]. Over 80% of patients are highly responsive to frontline treatment, but 60-70% experience disease recurrence within 2-5 years and ultimately succumb to their disease [2], [3].
###end p 9
###begin p 10
###xml 244 247 244 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Holschneider1">[4]</xref>
###xml 249 252 249 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Ozols2">[5]</xref>
###xml 382 385 382 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Nelson1">[6]</xref>
###xml 387 390 387 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Gimotty1">[7]</xref>
###xml 398 405 398 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et. al.</italic>
###xml 536 539 536 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Zhang1">[8]</xref>
###xml 586 589 586 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Raspollini1">[9]</xref>
###xml 591 595 591 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Tomsova1">[10]</xref>
###xml 679 683 679 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Sato1">[11]</xref>
###xml 685 689 685 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Hamanishi1">[12]</xref>
###xml 789 793 789 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Bamias1">[13]</xref>
###xml 943 947 935 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Marth1">[14]</xref>
###xml 949 953 941 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Kusuda1">[15]</xref>
###xml 978 982 966 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Duncan1">[16]</xref>
###xml 990 994 978 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Akahiro1">[17]</xref>
###xml 1012 1016 1000 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Rolland1">[18]</xref>
###xml 1018 1022 1006 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Moore1">[19]</xref>
###xml 1194 1198 1182 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Sato1">[11]</xref>
###xml 1200 1204 1188 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Wolf1">[20]</xref>
###xml 1205 1209 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Woo1">[22]</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
Despite these unfortunate statistics, 20-30% of EOC patients survive five years or more after diagnosis. Favorable prognostic factors include early stage, non-serous histology, low grade, good performance status, and optimal surgical debulking [4], [5]. In addition, several recent studies have shown a correlation between tumor-infiltrating CD3+CD8+ T cells and favorable outcomes [6], [7]. Zhang et. al. first reported that patients with CD3+ T cell infiltrates in tumor epithelium had increased progression-free and overall survival [8]. This has been confirmed by two other studies [9], [10], and two groups have extended this finding to the CD8+ T cell subset in particular [11], [12]. In addition, the presence of CD3+CD56+ T cells in ascites has been linked to platinum sensitivity [13]. These findings are in agreement with earlier studies showing a positive correlation between survival and expression of interferon-gamma (IFN-gamma) [14], [15], the IFN-gamma receptor [16], IL-18 [17], and MHC class I [18], [19], all of which are characteristic of CD8+ T cell responses. In contrast, the presence of tumor-infiltrating CD25+FoxP3+ T cells in EOC is correlated with inferior survival [11], [20]-[22]. Thus, it appears that the balance of CD8+ effector T cells to CD25+FoxP3+ regulatory T cells is an important determinant of clinical outcomes in EOC.
###end p 10
###begin p 11
###xml 185 189 185 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Luborsky1">[23]</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Chatterjee1">[25]</xref>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Wasserfall1">[26]</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 400 408 <span type="species:ncbi:9606">patients</span>
In addition to tumor-infiltrating T cells, many EOC patients mount serum autoantibody responses to a variety of tumor antigens, including NY-ESO-1, HOXA7, Ep-CAM, HSP-90, MUC-1 and p53 [23]-[25]. In Type I diabetes and other autoimmune conditions, the development of autoantibody responses portends tissue infiltration and destruction by autoreactive T cells [26]. We therefore hypothesized that EOC patients may show a similar relationship between tumor-specific autoantibody responses and tumor-infiltrating lymphocytes. This hypothesis was tested in a cohort of 35 advanced stage, high grade serous EOC cases for which matched serum and tumor specimens were available. Using NY-ESO-1 as a test antigen, we demonstrate for the first time a correlation between tumor-specific autoantibodies and tumor-infiltrating T cells. Our findings raise the possibility that autoantibodies may play a role in the previously recognized relationship between tumor-infiltrating T cells and clinical outcomes in EOC.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Study cohort
###end title 13
###begin p 14
###xml 217 224 217 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003409-t001">Table 1</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Gilks1">[27]</xref>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
###xml 635 640 <span type="species:ncbi:9606">women</span>
We investigated the relationship between tumor-specific autoantibodies and tumor-infiltrating lymphocytes using matched tumor and serum specimens from a retrospective cohort of 35 patients with high-grade serous EOC (Table 1). We elected to focus on a single histological subtype, as other subclasses of EOC exhibit distinct biological and clinical properties that might have confounded the analysis [27]. All blood samples were collected prior to surgery or chemotherapy, and all tumor specimens were obtained at the time of primary cytoreductive surgery prior to chemotherapy. Control blood samples were obtained from 60 age-matched women with no known personal history of cancer.
###end p 14
###begin title 15
###xml 46 53 <span type="species:ncbi:9606">patient</span>
Clinical characteristics of the retrospective patient cohort.
###end title 15
###begin p 16
There were no deaths due to causes other than ovarian cancer, therefore disease-specific and overall survival were equivalent.
###end p 16
###begin title 17
Analysis of tumor-infiltrating lymphocytes
###end title 17
###begin p 18
###xml 131 139 131 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g001">Figure 1</xref>
###xml 141 148 141 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003409-t002">Table 2</xref>
###xml 198 207 198 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003409.s001">Tables S1</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003409.s002">S2</xref>
Tumor-infiltrating lymphocytes were assessed by immunohistochemistry (IHC) using antibodies to a variety of immunological markers (Figure 1, Table 2). All raw IHC data can be found in Supplementary Tables S1 and S2. Only 23% (8/35) of evaluable tumors showed significant CD20+ B cell infiltrates. In contrast, 94% (33/35) of tumors had detectable CD3+ T cell infiltrates. Staining with antibodies to CD4 and CD8 revealed that 59% (20/34) and 69% (24/35) of evaluable tumors had significant CD4+ and CD8+ cellular infiltrates, respectively. CD4+ and CD8+ cells were strongly correlated (r = 0.69, p<0.0001). All evaluable tumors (27/27) expressed MHC class I to some degree, indicating they could theoretically present antigen to the infiltrating CD8+ T cells. Seventy-two percent (18/25) of tumors expressed MHC class II and hence could theoretically present antigen to CD4+ T cells.
###end p 18
###begin title 19
Immunohistochemical analysis of serous ovarian tumors showing cases with high (left) and low (right) scores for the following markers: (A,B) CD20; (C,D) CD3; (E,F) CD4; (G,H) CD8; (I,J) MHC Class I; and (K,L) MHC Class II.
###end title 19
###begin title 20
Primary antibodies used for immunohistochemistry.
###end title 20
###begin p 21
###xml 185 189 185 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Pipkin1">[28]</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Kanavaros1">[30]</xref>
###xml 361 369 361 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g002">Figure 2</xref>
Since many tumors had dense CD8+ T cell infiltrates, we analyzed tissues for TIA-1 and Granzyme B, both of which are expressed by CD8+ cytotoxic T cells as well as natural killer cells [28]-[30]. Seventy-three percent (25/34) of tumors had significant TIA-1+ cellular infiltrates, which showed a positive correlation with CD8+ infiltrates (r = 0.83, p<0.0001) (Figure 2). In contrast, only 20% (7/35) of the tumors had significant Granzyme B+ cellular infiltrates (data not shown); as expected, 6 of the 7 positive tumors were also positive for CD8+ cells.
###end p 21
###begin title 22
Immunohistochemical analysis of serous ovarian tumors showing cases with high (left) and low (right) scores for the following markers: (A,B) TIA-1; (C,D) FoxP3; and (E,F) CD25.
###end title 22
###begin p 23
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Ziegler1">[31]</xref>
###xml 210 218 210 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g002">Figure 2</xref>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Zou1">[32]</xref>
###xml 465 473 465 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g002">Figure 2</xref>
Tumors were also analyzed for cellular infiltrates expressing FoxP3, a marker of activated T cells and regulatory T cells [31]. Sixty-six percent (23/35) of evaluable tumors had significant FoxP3+ infiltrates (Figure 2), which were strongly correlated to CD4+ cells (r = 0.73, p<0.0001). We also evaluated expression of CD25, an additional marker of activated and regulatory T cells [32]. Fifty percent (17/34) of tumors had significant CD25+ cellular infiltrates (Figure 2), which were strongly correlated with CD4+ cells (r = 0.58, p = 0.0003) and FoxP3+ cells (r = 0.75, p<0.0001).
###end p 23
###begin p 24
###xml 212 215 212 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Zhang1">[8]</xref>
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Hamanishi1">[12]</xref>
###xml 438 445 438 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003409-t003">Table 3</xref>
###xml 1039 1046 1039 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003409-t003">Table 3</xref>
We further stratified T cell infiltrates according to their epithelial or stromal location within the tumor, as intraepithelial CD3+/CD8+ T cells in particular have been correlated with increased survival in EOC [8]-[12]. For this analysis, we first measured the tumor composition as defined by the epithelial:stromal ratio in each tissue core and then calculated the density of T cells per unit of epithelium or stroma. As summarized in Table 3, the density of CD3+ T cells per unit of tumor epithelium ranged from 0-17, with a median of 4.6. In comparison, the density of CD3+ T cells per unit of tumor stroma ranged from 0-138, with a median of 16.3. In general, the density of CD3+ T cells in tumor epithelium and stroma were only weakly correlated (r = 0.34, p = 0.048), and there were many examples of tumors with dense CD3+ infiltrates in epithelium but not stroma, and conversely, in stroma but not epithelium. Similar to CD3+ cells, CD8+, CD4+, FoxP3+ and TIA-1+ cells were generally denser in tumor stroma than tumor epithelium (Table 3).
###end p 24
###begin title 25
Density of lymphocyte subsets in tumor stroma versus epithelium.
###end title 25
###begin p 26
All values are reported as cells per unit area defined by the Chalkley grid.
###end p 26
###begin title 27
Composition of tumor-infiltrating lymphocytes after neoadjuvant chemotherapy
###end title 27
###begin p 28
###xml 89 94 <span type="species:ncbi:9606">women</span>
###xml 256 261 <span type="species:ncbi:9606">women</span>
The TMA used in the above analyses also contained an additional cohort of 15 tumors from women who, as part of a clinical trial, had undergone neoadjuvant platinum/taxane-based chemotherapy prior to their primary surgery. As with the 35-case cohort, these women had high-grade serous EOC. Tumors had been resected after three cycles of carboplatinum/taxol-based chemotherapy. Although the sample size was small, this provided a unique opportunity to evaluate the effects of chemotherapy on tumor-infiltrating lymphocytes. By most parameters, lymphocytic infiltrates were similar between treated and untreated tumors. However, treated tumors showed a uniform trend towards increased infiltration by all subsets of T cells assessed, and this increase was significantly higher for CD3+ (median 80 vs 35, p = 0.02) and CD8+ (median 78 vs 30, p = 0.013) cells (data not shown).
###end p 28
###begin title 29
Serum autoantibody responses to NY-ESO-1
###end title 29
###begin p 30
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Luborsky1">[23]</xref>
###xml 107 111 107 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Chatterjee1">[25]</xref>
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Stone1">[24]</xref>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Odunsi1">[33]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Yakirevich1">[34]</xref>
###xml 356 365 356 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003409.s001">Tables S1</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003409.s002">S2</xref>
###xml 676 685 676 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g003">Figure 3A</xref>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Although ovarian cancer patients demonstrate autoantibody responses to a broad repertoire of antigens [23]-[25], we focused on one of the most immunogenic antigens, NY-ESO-1 [24], [33], [34]. Sixty control sera were assayed for IgG autoantibodies to recombinant NY-ESO-1, and the mean and standard deviation of the OD values were calculated (Supplementary Tables S1 and S2). Individual sera were scored as positive if their OD value was equal to or greater than two standard deviations from the mean of control subjects. Consistent with published results, 26% (9/35) of ovarian cancer cases demonstrated IgG autoantibodies to NY-ESO-1, compared to only 5% (3/60) of controls (Figure 3A).
###end p 30
###begin title 31
NY-ESO-1 serum autoantibodies and antigen expression in high-grade serous ovarian cancer.
###end title 31
###begin p 32
###xml 55 62 <span type="species:ncbi:9606">patient</span>
(A) Serum autoantibody responses to NY-ESO-1 in the 35-patient cohort. Autoantibody responses are reported as the number of standard deviations from the mean of 60 age- and gender-matched controls with no known personal history of cancer. (B,C) Immunohistochemical analysis of NY-ESO-1 expression in two representative serous ovarian tumors with high (B) and negative (C) expression of the antigen.
###end p 32
###begin p 33
###xml 258 267 258 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g003">Figure 3B</xref>
To determine whether autoantibody responses to NY-ESO-1 correlated with expression of the corresponding antigen, matched tumor specimens were analyzed by IHC for expression of NY-ESO-1. Of 34 evaluable tumors, 5 (14.7%) scored positive for NY-ESO-1 antigen (Figure 3B). All five of these cases were also positive for autoantibodies to NY-ESO-1. In contrast, 4 cases were positive for NY-ESO-1-specific autoantibodies but negative for NY-ESO-1 antigen expression.
###end p 33
###begin title 34
Correlations between autoantibody responses and lymphocytic infiltrates
###end title 34
###begin p 35
###xml 398 407 398 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003409.s001">Tables S1</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003409.s002">S2</xref>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
We next investigated whether serum autoantibodies to NY-ESO-1 were correlated with tumor-infiltrating lymphocytes. For this analysis, we considered epithelial and stromal T cell infiltrates separately, as described above. We classified cases as being positive or negative for autoantibodies to NY-ESO-1 using a cut-point of two standard deviations from the mean of the control group (Supplementary Tables S1 and S2). By Mann Whitney t test, patients with autoantibodies to NY-ESO-1 had a significantly greater stromal density of CD8+ cells (p = 0.011), FoxP3+ cells (p = 0.013), and CD4+ cells (p = 0.026). Thus, autoantibodies to NY-ESO-1 showed a significant correlation to T cell infiltrates, especially in tumor stroma.
###end p 35
###begin title 36
###xml 92 99 <span type="species:ncbi:9606">patient</span>
Recognition of NY-ESO-1 by autoantibodies and tumor-infiltrating CD8+ T cells from the same patient
###end title 36
###begin p 37
###xml 558 567 558 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g004">Figure 4A</xref>
###xml 866 875 862 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g004">Figure 4B</xref>
###xml 926 929 922 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neu</italic>
###xml 1197 1206 1193 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g004">Figure 4C</xref>
###xml 1531 1540 1527 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g004">Figure 4C</xref>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 641 648 <span type="species:ncbi:9606">patient</span>
###xml 1106 1113 <span type="species:ncbi:9606">patient</span>
###xml 1273 1281 <span type="species:ncbi:9606">patients</span>
###xml 1400 1407 <span type="species:ncbi:9606">patient</span>
###xml 1488 1495 <span type="species:ncbi:9606">patient</span>
The correlation between autoantibodies to NY-ESO-1 and tumor-infiltrating T cells suggested the possibility that tumor-infiltrating T cells may recognize NY-ESO-1 in seropositive patients. To address this issue, we collected blood, tumor and ascites specimens from a prospective cohort of 15 newly diagnosed serous EOC patients. Two patients were positive for serum autoantibodies to NY-ESO-1. Of these, one case (IROC013) was HLA-A2+, allowing T cells to be enumerated by flow cytometry with HLA-A2 pentamers loaded with a known CD8+ epitope from NY-ESO-1 (Figure 4A). NY-ESO-1-specific CD8+ T cells were rare in peripheral blood from this patient (0.22% of CD8+ cells), but were enriched in ascites and solid tumor (1.53% and 6.64% of CD8+ cells, respectively). Furthermore, T cells from ascites and solid tumor produced IFN-gamma in response to NY-ESO-1 peptide (Figure 4B) but not control peptides derived from p53, HER-2/neu or WT-1 (data not shown). Indeed, in ascites the response to NY-ESO-1 was almost as strong as that seen to the CEF viral control peptides. Intriguingly, tumor tissue from this patient showed dense CD3+ and CD8+ T cell infiltration of tumor stroma but not epithelium (Figure 4C), similar to the pattern commonly seen with autoantibody-positive patients in the retrospective cohort. Despite mounting a strong humoral and T-cell response to NY-ESO-1, solid tumor from this patient stained negative for expression of NY-ESO-1 antigen; however, ascites from this patient contained NY-ESO-1-positive cells (Figure 4C).
###end p 37
###begin title 38
###xml 37 44 <span type="species:ncbi:9606">patient</span>
Analysis of the T cell response in a patient with autoantibodies to NY-ESO-1 showing the presence of NY-ESO-1 reactive CD8+ T cells in ascites and tumor despite the lack of NY-ESO-1 expression in solid tumor.
###end title 38
###begin p 39
###xml 460 461 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
(A) MHC class I pentamer analysis demonstrating enrichment of NY-ESO-1-specific CD8+ T cells in ascites and solid tumor compared to peripheral blood. The boxed areas and associated numbers represent the percentage of pentamer-positive cells relative to total CD8+ cells. (B) ELISPOT analysis of IFN-gamma production by T cells after stimulation with an HLA-A2-binding peptide from NY-ESO-1. Data is presented as the number of IFN-gamma-producing cells per 1x106 bulk cells from the indicated tissue compartments. (C) Immunohistochemical analysis of tumor-infiltrating CD3+ and CD8+ T cells in tumor stroma, and expression of NY-ESO-1 antigen. While the solid tumor was negative for expression of NY-ESO-1, a fraction of cells from ascites were positive. The cellular fraction of ascites also contained cytokeratin-positive epithelial cells, presumably of tumor origin (data not shown).
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 270 275 <span type="species:ncbi:9606">human</span>
###xml 472 479 <span type="species:ncbi:9606">patient</span>
Using matched serum and tumor specimens from 35 patients with high-grade serous EOC, we have demonstrated a correlation between tumor-infiltrating T cells and tumor-specific autoantibodies. To our knowledge, this is the first study to identify such a correlation in any human cancer. Specifically, the presence of NY-ESO-1-specific IgG autoantibodies in serum correlated with infiltration of tumor stroma by cells expressing CD8, CD4 and FoxP3. Moreover, in an individual patient with autoantibodies to NY-ESO-1, corresponding ascites and solid tumor specimens were shown to be enriched for NY-ESO-1-reactive CD8+ T cells, as assessed by MHC class I pentamer staining and IFN-gamma ELISPOT. These findings raise the possibility that autoantibody responses may collaborate with tumor-infiltrating T cells to influence clinical outcomes in EOC.
###end p 41
###begin p 42
###xml 205 208 205 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Zhang1">[8]</xref>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Negus1">[35]</xref>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Shah1">[36]</xref>
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Kooi1">[37]</xref>
###xml 349 352 349 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Zhang1">[8]</xref>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Hamanishi1">[12]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-HelalTel1">[38]</xref>
###xml 425 429 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Buckanovich1">[39]</xref>
In addition to NY-ESO-1-specific autoantibodies, several factors expressed by ovarian tumors have shown a positive correlation with tumor-infiltrating T cells, including the chemokines CXCL9, CCL21, CCL22 [8], CCL2 and CCL5 [35]; p53 mutations [36]; and MHC class I [37]. Conversely, tumor-infiltrating T cells show a negative correlation with VEGF [8], B7-H1/PD-L1 [12], CD68+ macrophages [38] and the endothelin B receptor [39]. Thus, multiple factors influence the composition of tumor-infiltrating T cells in EOC.
###end p 42
###begin p 43
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Luborsky1">[23]</xref>
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Chatterjee1">[25]</xref>
###xml 448 452 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Stone1">[24]</xref>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
While this study focused on a single, commonly recognized tumor antigen, NY-ESO-1, a large number of other autoantibody target antigens have been identified in EOC, including HOXA7, Ep-CAM, HSP-90, MUC-1 and p53 [23]-[25]. Indeed, tumor-specific autoantibody responses are common among EOC patients. For example, Stone et al. found that 44% of newly diagnosed EOC patients had an autoantibody response to at least 1 of a panel of 12 tumor antigens [24]. Future work will determine whether autoantibody responses to other tumor antigens also correlate with the presence of tumor-infiltrating T cells.
###end p 43
###begin p 44
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Hayashi1">[40]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Peoples2">[44]</xref>
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Goedegebuure1">[45]</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Freedman1">[50]</xref>
###xml 482 485 482 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neu</italic>
###xml 485 489 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Peoples2">[44]</xref>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Yoshino1">[51]</xref>
###xml 496 500 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Linehan1">[53]</xref>
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Lambeck1">[54]</xref>
###xml 538 542 538 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Peoples6">[55]</xref>
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Peoples7">[56]</xref>
###xml 1440 1444 1436 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Geisler1">[57]</xref>
###xml 1446 1450 1442 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Hilton1">[58]</xref>
###xml 799 806 <span type="species:ncbi:9606">patient</span>
###xml 907 914 <span type="species:ncbi:9606">patient</span>
In contrast to serological responses, less is known about the target antigens of tumor-infiltrating T cells in EOC. T cell receptor (TCR) spectratyping studies have shown that tumor-infiltrating T cells in EOC represent oligoclonal populations, which is consistent with antigen-induced clonal expansion [40]-[44]. Many studies have shown recognition of autologous tumor cells by tumor-infiltrating T cells [45]-[50]. Moreover, previous work has identified T cells specific for HER2/neu[44], [51]-[53], p53 [54] and folate-binding protein [55], [56] among tumor-infiltrating or tumor-associated T cells. To our knowledge, the current study is the first to demonstrate recognition of NY-ESO-1 by tumor-infiltrating and tumor-associated (i.e., ascites derived) T cells, as evidenced by the results for patient IROC013. Intriguingly, T cell responses to NY-ESO-1 were undetectable in peripheral blood from this patient, indicating a strong enrichment of this T cell subpopulation in tumor and ascites. Indeed, the IFN-gamma ELISPOT response to NY-ESO-1 was similar in magnitude to that seen with CEF control peptides. Nonetheless, the NY-ESO-1-specific subpopulation represented only 6.6% of all tumor-infiltrating CD8+ T cells in this subject, indicating there are likely many other antigens recognized by infiltrating T cells. Notably, over 80% of ovarian cancers exhibit loss of BRCA1 and/or BRCA2 function, leading to compromised DNA repair[57], [58]. One can speculate that the resulting genetic instability leads to the expression of abnormal proteins that may serve as neoantigens to the host immune system.
###end p 44
###begin p 45
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Sato1">[11]</xref>
###xml 573 577 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Hamanishi1">[12]</xref>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Wolf1">[20]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Curiel1">[21]</xref>
###xml 745 749 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Marth1">[14]</xref>
###xml 751 755 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Kusuda1">[15]</xref>
###xml 780 784 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Duncan1">[16]</xref>
###xml 795 799 787 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Akahiro1">[17]</xref>
###xml 874 878 866 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Rolland1">[18]</xref>
###xml 880 884 872 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Moore1">[19]</xref>
###xml 1061 1065 1053 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Nijman1">[59]</xref>
###xml 1302 1310 1294 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1310 1314 1302 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Peoples1">[43]</xref>
###xml 1316 1320 1308 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Goedegebuure1">[45]</xref>
###xml 1322 1326 1314 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Ioannides1">[47]</xref>
###xml 1328 1332 1320 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Santin1">[60]</xref>
###xml 1334 1338 1326 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Ioannides2">[61]</xref>
###xml 1423 1427 1415 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Nijman1">[59]</xref>
###xml 1537 1544 1529 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1640 1644 1632 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Hayashi1">[40]</xref>
###xml 1645 1649 1637 1641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Peoples2">[44]</xref>
###xml 1687 1691 1679 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Peoples2">[44]</xref>
###xml 1693 1697 1685 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Yoshino1">[51]</xref>
###xml 1698 1702 1690 1694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Peoples7">[56]</xref>
###xml 1732 1740 1724 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003409-g004">Figure 4</xref>
###xml 2052 2056 2044 2048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Galon1">[62]</xref>
Although tumor infiltrating T cells are associated with prolonged progression-free and overall survival in EOC, it remains unclear whether this reflects an active or passive role of T cells. In other words, do T cells actively oppose tumor growth or are they simply markers of some other feature of the tumor that drives outcomes? There are several lines of evidence in support of the former possibility. First, not all T-cell subsets are associated with prognosis; rather, favorable outcomes are linked to the CD8+ subset and poor outcomes to the CD25+FoxP3+ subset [11], [12], [20], [21]. Second, several factors that are associated with active CD8+ cytolytic responses are also linked to favorable outcomes, including expression of IFN-gamma [14], [15], the IFN-gamma receptor [16] and IL-18 [17]. MHC class I has also been linked to increased survival in ovarian cancer [18], [19]. In the present study, which focused exclusively on the serous subtype, all evaluable tumors expressed MHC class I. Similar results have been reported by others for serous EOC [59], suggesting the vast majority of serous tumors are MHC class I positive and have the capacity to present antigen to tumor-infiltrating CD8+ T cells. Third, tumor-infiltrating T cells show significant cytotoxicity against ovarian tumors in vitro[43], [45], [47], [60], [61]. However, it is noteworthy that only a minority of tumors in this and another study [59] had significant Granzyme B-positive immune infiltrates, suggesting that cytotoxic function may be suppressed in vivo. And finally, as discussed above, tumor-infiltrating T cells show evidence of clonal expansion [40]-[44] and recognition of specific antigens [44], [51]-[56], as shown here for NY-ESO-1 (Figure 4). Thus, evidence is accumulating in favor of the concept that tumor-infiltrating T cells play an active role in promoting favorable clinical outcomes in EOC. Similarly, in colorectal cancer, functional markers associated with active Th1-like cytolytic T cell responses are linked to favorable clinical outcomes [62]. This suggests that immune modulatory strategies that enhance these naturally occurring T cell responses may improve clinical outcomes further.
###end p 45
###begin p 46
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Goodell1">[63]</xref>
###xml 442 446 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Vogl1">[64]</xref>
###xml 448 452 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Mayerhofer1">[65]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Hogdall1">[66]</xref>
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Gadducci1">[67]</xref>
###xml 725 729 725 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Stone1">[24]</xref>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
###xml 966 973 <span type="species:ncbi:9606">patient</span>
In contrast to T cell infiltrates, the relationship between tumor-specific autoantibodies and clinical outcomes is less clear. This issue has been studied most extensively for the tumor antigen p53, which elicits autoantibody responses in 20-25% of EOC patients. Goodell et. al. reported a positive correlation between autoantibodies to p53 and increased overall survival in EOC [63]. However, other studies have found a negative correlation [64], [65] or no correlation [66], [67]. As for NY-ESO-1, we found a trend toward poor outcomes among patients with autoantibodies to NY-ESO-1 in the 35-case cohort studied here (data not shown), but this trend was not seen in an independent cohort of 35 patients from a prior study [24] (data not shown). As discussed above, the immune response to EOC involves multiple antigens, therefore we believe that the prognostic significance of autoantibodies is best addressed using an extended panel of tumor antigens and larger patient cohorts.
###end p 46
###begin p 47
###xml 712 716 712 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Crane1">[68]</xref>
###xml 1072 1076 1072 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Qin1">[69]</xref>
###xml 1368 1372 1368 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Qin1">[69]</xref>
###xml 1710 1714 1710 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Zou1">[32]</xref>
###xml 766 774 <span type="species:ncbi:9606">patients</span>
###xml 972 978 <span type="species:ncbi:10090">murine</span>
###xml 1819 1827 <span type="species:ncbi:9606">patients</span>
The autoantibody response to NY-ESO-1 correlated to T cell infiltration of tumor stroma as opposed to tumor epithelium. This may reflect a statistical issue, as the absolute number of T cells was higher in tumor stroma compared to epithelium, allowing the stromal values to achieve statistical significance. Indeed, Spearman rank correlation analysis showed a positive relationship between autoantibodies to NY-ESO-1 and infiltration of tumor epithelium by CD3+ and CD8+ cells, but this did not reach statistical significance (data not shown). Alternatively, there may be a biological explanation. In the Th1/Th2 paradigm, immune responses are thought to polarize toward humoral or cytolytic effector mechanisms [68]. Applied to our results, this would suggest that patients with strong autoantibody responses would have weak cytolytic responses, which may result in incomplete (i.e., stromal) infiltration of tumor tissue by T cells. A second possibility is suggested by murine models where autoantibody responses have been linked to weak CD8+ cytolytic T cell responses [69]. In this case, it was proposed that autoantibodies facilitate uptake and presentation of tumor antigens by B cells at the expense of dendritic cells. Since B cells are less potent antigen presenting cells than dendritic cells, the net result is an inferior T cell response against the tumor [69]. A final consideration is that, in the present study, autoantibody responses to NY-ESO-1 were correlated with infiltration of tumor by not only CD8+ T cells, but also by CD4+ and FoxP3+ T cells. The latter cells may represent regulatory T cells, which could inhibit cytolytic T cells responses and limit the extent of tumor infiltration [32]. We are currently collecting matched blood and tumor specimens from a larger, prospective cohort of EOC patients to better understand the relationship between tumor-specific autoantibodies, tumor-infiltrating T cells and clinical outcomes.
###end p 47
###begin p 48
###xml 438 442 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Demaria1">[70]</xref>
###xml 460 464 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Ladoire1">[71]</xref>
###xml 595 599 595 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Tsavaris1">[72]</xref>
###xml 600 604 600 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Fitzpatrick1">[75]</xref>
###xml 630 634 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Tsuda1">[76]</xref>
###xml 710 714 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Riesbeck1">[77]</xref>
###xml 752 756 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Tsuda2">[78]</xref>
###xml 807 811 807 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Bagnoli1">[79]</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 696 701 <span type="species:ncbi:9606">human</span>
###xml 967 974 <span type="species:ncbi:9606">patient</span>
Although not the primary focus of this paper, we had the opportunity to assess the effect of neoadjuvant chemotherapy on tumor-infiltrating T cells in 15 patients. In general, treated tumors showed increased infiltration by all subsets of T cells, and this reached statistical significance for CD3+ and CD8+ cells. This is reminiscent of studies in breast cancer which showed increased T cell infiltration after chemotherapy with taxanes [70] and other agents [71] and an association with favorable clinical responses. Taxanes may also promote tumor immunity by enhancing T and NK cell activity [72]-[75] and antigen presentation [76]. Likewise, platinum agents can enhance cytokine synthesis by human T cells [77], abrogate suppressor T cell activity [78] and sensitize EOC cells to Fas-mediated apoptosis [79]. Thus, platinum/taxane-based chemotherapy may have favorable effects on host immunity to EOC, a hypothesis we are currently investigating in a prospective patient cohort.
###end p 48
###begin p 49
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Freedman1">[50]</xref>
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Stewart1">[80]</xref>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003409-Fujimoto1">[89]</xref>
###xml 303 310 <span type="species:ncbi:9606">patient</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
Several groups have attempted adoptive immunotherapy of ovarian cancer using T cells expanded from tumor-infiltrating T cells [50], [80]-[89]. Although promising anecdotal responses have been reported, these efforts have generally met with limited success. It is noteworthy that solid tumor tissue from patient IROC013 was largely negative for expression of NY-ESO-1, despite having NY-ESO-1-specific T cells in tumor and ascites. If this scenario is representative of other EOC patients, it would suggest that many tumor-infiltrating T cells may recognize antigens that are poorly expressed by tumor tissue, possibly due to immune selection during tumor development. If we are to realize the promise of immunotherapy for EOC, there is a pressing need to identify target antigens that are essential to the growth and survival of recurrent, chemotherapy-resistant tumors. Our results suggest that autoantibody responses hold practical value for antigen identification and warrant further study with respect to their role in host tumor immunity and clinical outcomes.
###end p 49
###begin title 50
Materials and Methods
###end title 50
###begin title 51
Study subjects
###end title 51
###begin p 52
###xml 471 478 471 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003409-t001">Table 1</xref>
###xml 232 237 <span type="species:ncbi:9606">women</span>
###xml 613 618 <span type="species:ncbi:9606">women</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
###xml 927 932 <span type="species:ncbi:9606">women</span>
All specimens and clinical data were obtained with informed consent under protocols approved by the Research Ethics Board of the BC Cancer Agency and the University of British Columbia. The retrospective case cohort consisted of 35 women with high-grade serous ovarian cancer from whom matched serum and tumor tissue was available (OvCaRe Ovarian Tumour Bank, Vancouver, BC, Canada). Tumor tissue was obtained at the time of primary surgery prior to any other treatment. Table 1 shows the general clinical characteristics of the 35-case cohort. The retrospective cohort also included tissue from an additional 15 women who received neoadjuvant chemotherapy prior to primary surgery; these cases are discussed separately in Results. Blood, ascites and tumor samples were also collected from a prospective cohort of 15 patients through the BC Cancer Agency's Tumour Tissue Repository. Control serum samples were obtained from 60 women with no known personal history of ovarian cancer or other cancers. All control subjects self reported receiving a negative mammographic result within the past year. The age distribution of the control cohort (mean 62.0 years, standard deviation 12.3 years, range 45.9 to 88.9 years) was similar to that of the case cohort.
###end p 52
###begin title 53
Tumor and serum specimens
###end title 53
###begin title 54
Retrospective cohort
###end title 54
###begin p 55
Tumor tissue was obtained during primary cytoreductive surgery. Tissue had an ischemia time of less than 30 minutes and spent less than 48 hours in formalin prior to being processed in paraffin. A tissue microarray (TMA) was constructed by taking duplicate 0.6 mm cores from tumor blocks after review of hematoxylin- and eosin-stained sections by a pathologist. Cores were selected from regions of tumor containing representative proportions of epithelium and stroma, while avoiding highly necrotic regions. TMAs were assembled using a Pathology Devices tissue arrayer (Westminster, MD). Serum samples from cases were collected prior to surgery or chemotherapy. Blood samples were processed by standard laboratory procedures.
###end p 55
###begin title 56
Prospective cohort
###end title 56
###begin p 57
###xml 610 611 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Blood was collected prior to surgery in heparanized Vacutainer tubes, and peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density centrifugation. HLA-A2 status was determined by flow cytometry on a FACSCalibur (BD Biosciences, San Jose, CA) after surface staining PBMC with anti-HLA-A2 antibody (clone BB7.2, BD Pharmingen, San Diego, CA). Ascites collected during surgery was centrifuged (1200 rpm for 10 min), and red blood cells (RBCs) were removed by treatment with ACK lysis buffer (Sigma, St. Louis, MO). Solid tumor removed during surgery was minced with scalpels to approximately 2 mm2 and was then digested overnight at 4degreesC in RPMI 1640 (Invitrogen, Carlsbad, CA) containing collagenase Type I and IV (each at 0.05 mg/ml), 0.025 mg/ml hyaluronidase and 0.01 mg/ml DNAse I (all from Sigma, St. Louis, MO). After digestion, material was passed through a 100 microm sterile cell strainer to remove clumps, and the resulting single-cell suspension was pelleted as described above.
###end p 57
###begin title 58
Immunohistochemistry and immunocytochemistry
###end title 58
###begin p 59
###xml 374 381 364 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003409-t002">Table 2</xref>
TMAs were sectioned at 5 microm onto Superfrost plus slides (Fisher Scientific, Ottawa, ON) and incubated overnight at 37degreesC. Following deparaffinization, the slides were placed in a Ventana Discovery XT autostainer (Ventana, Tucson, AZ) for immunohistochemical staining. Ventana's standard CC1 protocol was used for antigen retrieval. Primary antibodies are listed in Table 2.
###end p 59
###begin p 60
TMAs were incubated with primary antibodies for 60 minutes, and the appropriate cross-adsorbed, biotinylated secondary antibody (Jackson Immunoresearch, West Grove, PA) was applied for 32 minutes. Bound antibodies were detected using the DABMap kit (Ventana), counterstained with hematoxylin (Ventana), and coverslipped manually with Cytoseal-60 (Richard Allan, Kalamazoo, MI).
###end p 60
###begin p 61
###xml 382 389 376 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003409-t002">Table 2</xref>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 295 302 <span type="species:ncbi:9606">patient</span>
Ascites from serous ovarian cancer patients was collected and centrifuged using a Cytospin III cytocentrifuge (Thermo Shandon, Waltham, MA). The slides were then fixed in acetone and stored at -80degreesC until subjected to immunohistochemistry using standard protocols. The ascites sample from patient IROC013 was stained with antibodies to NY-ESO-1, CD3, CD8 and pan-cytokeratin (Table 2).
###end p 61
###begin title 62
Histopathological analysis
###end title 62
###begin p 63
###xml 1374 1375 1372 1373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Immunostained TMAs were examined independently by two pathologists and a high degree of inter-observer concordance was achieved (r>0.7, p<0.0001) as well as intra-observer concordance on different sessions (r = 0.79, p<0.0001). Although the TMAs showed reasonable core retention, some cores were lost during the sectioning process and were not evaluable for one or more markers. Immunostaining was scored using three semi-quantitative IHC scoring systems. For NY-ESO-1 antigen, a modified H score approach was used [IHC score = (% positive neoplastic epithelial cells)x(staining intensity ranked from 0 to 3)] that ranged from 0-300. Positive was defined as an H score greater than 10; in practice, negative cases had H scores of 0-5, whereas positive cases had H scores ranging from 105-250. For MHC class I and II, a simplified four category scale was used (0 to 3+); a score of >/=2 was defined as positive. For immune cells, scoring was undertaken using a Chalkley 25 point array and methods similar to those used to assess vascular density. Briefly, each immunostained tumor was reviewed at low magnification and the core with the highest density of positive cells was selected. This core was then assessed at higher magnification (x20 objective) with a 25 cross hair grid overlaid on the image. Under a x20 objective magnification, this grid defines an area of 0.56 mm2. The proportion of the core occupied by tumor epithelium was estimated, as was the total number of positive immune cells within the area of the grid. The number of grid points that coincided with positively staining immune cells within both epithelial and stromal areas was then determined. Positive immune cells that touched or overlapped with tumor epithelial compartments were counted as intraepithelial. All other positive cells were counted as intrastromal. For subsequent statistical analyses, an epithelial or stromal region was considered positive for a given immune cell population if there were more than five cells per unit area.
###end p 63
###begin title 64
ELISA to detect serum autoantibodies to NY-ESO-1
###end title 64
###begin p 65
###xml 362 369 362 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 362 369 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
A cDNA encoding NY-ESO-1 was amplified by reverse-transcriptase PCR from the ovarian cancer cell line OVCAR-3. The C-terminal 25 amino acids were truncated to improve solubility of the protein. After sequencing, the cDNA was subcloned into the prokaryotic expression vector pDEST17, which adds a six-residue histidine tag at the N-terminus, and expressed in the E. coli strain BL21AI (Invitrogen, Carlsbad, CA). Urea-soluble recombinant NY-ESO-1 was purified on a HisTraptrade mark column (GE Healthcare, Fairfield Conn), eluted in urea buffer containing 500 mM imidazole, dialyzed in phosphate-buffered saline (PBS) and quantified by bicinchoninic acid (BCA) protein assay (Sigma, St. Louis, MO).
###end p 65
###begin p 66
###xml 141 142 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 144 145 140 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 158 159 154 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 255 261 <span type="species:ncbi:9913">bovine</span>
###xml 584 591 <span type="species:ncbi:9606">patient</span>
###xml 764 768 <span type="species:ncbi:9925">goat</span>
###xml 774 779 <span type="species:ncbi:9606">human</span>
###xml 798 809 <span type="species:ncbi:3704">horseradish</span>
Maxisorp 96-well plates (Nunc, Roskilde, Denmark) were coated with 0.5 microg/well of purified NY-ESO-1 in 0.1 M carbonate buffer (33.5 mM Na2CO3, 0.1 M NaHCO3, pH 9.6) and incubated overnight at 4degreesC with gentle rocking. Plates were blocked with 3% bovine serum albumin (US Biological, Swampscott MA) in Tris buffered saline (TBS) containing 0.05% Tween-20 (3% BSA/TBST) for 2 hours at room temperature on a rapid shaker. All washes were performed with TBS/0.1% Tween-20 using a Skanwasher plate washer (Molecular Devices, Union City, CA). Plates were washed and incubated with patient and control serum diluted 1:100 in 3% BSA/TBST for 1 hour at room temperature on a rapid shaker. All sera were assayed in triplicate. Plates were washed and incubated with goat anti-human IgG conjugated to horseradish peroxidase (Jackson, West Grove, PA) at 1:10,000 in 3% BSA/TBST for 1 hour on a shaker at room temperature. Plates were developed with tetramethylbenzidine (TMB) (Neogen, Lansing, MI) for 3 minutes at room temperature and the reaction was stopped by addition of 1N HCl. The optical density of each well was analyzed at 450 nm on a Versamax plate reader (Molecular Devices, Union City, CA) and analyzed using Softmax Pro 4.8.
###end p 66
###begin title 67
IFN-gamma ELISPOT analysis
###end title 67
###begin p 68
###xml 509 510 495 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 651 658 637 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">157&#8211;165</sub>
###xml 663 670 649 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">264&#8211;272</sub>
###xml 676 683 662 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">126&#8211;134</sub>
###xml 691 694 677 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neu</italic>
###xml 694 701 680 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">654&#8211;662</sub>
###xml 733 734 715 716 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 750 751 732 733 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</underline>
###xml 764 765 746 747 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</underline>
###xml 1377 1378 1331 1332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1050 1055 <span type="species:ncbi:9606">human</span>
ELISPOT plates (MSIP, Millipore, Billerica, MA) were pre-coated overnight with 10 microg/ml anti-IFN-gamma capture antibody (1-D1K-Mabtech, Cincinnati, OH) and then blocked for 2 hours at 37degreesC with cRPMI (RPMI 1640, 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, 10 mM HEPES, 10 mM MEM non-essential amino acids, 10 mM sodium pyruvate and 50 ug/ml gentamicin). Single cell suspensions of PBMC, ascites cells or solid tumor-derived cells were prepared in 10 ml cRPMI and plated in triplicate at 3x105 cells per well. Cells were either left unstimulated (i.e., media only) or stimulated with HLA-A2-restricted tumor antigen peptides (NY-ESO-1157-165, p53264-272, WT-1126-134, HER-2/neu654-662; each at 10 microg/ml); a CEF (Cytomegalovirus, Epstein Barr, Flu) virus positive control peptide pool (10 microg/ml, Anaspec, San Jose, CA); or the T-cell mitogen phytohemagglutinin (PHA) (5 microg/ml). After overnight incubation at 37degreesC, ELISPOT plates were washed and incubated for 2 hours at 37degreesC with 1 microg/ml biotinylated anti-human IFN-gamma (mAb 7-B6-1, Mabtech) followed by development with Vectastain ABC Elite kit and Vectastain AEC substrate reagent according to the manufacturer's instructions (Vector Labs, Burlingame, CA). Spots were quantified using a Zeiss automated ELISPOT reader and reported as the number of spot-forming cells (SFC) per 106 PBMC.
###end p 68
###begin title 69
MHC class I pentamer analysis
###end title 69
###begin p 70
###xml 121 128 121 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">157&#8211;165</sub>
Single-cell suspensions of ascites cells were depleted of red blood cells and stained with APC-conjugated HLA-A2-NY-ESO-1157-165 pentamer (Proimmune) according to the manufacturer's instructions. Pentamer staining was followed by surface staining with PerCP-conjugated anti-CD8 (53-6.7) (BD Pharmingen). Cells were analyzed on a BD FACSCalibur, and a minimum of 50,000 events were collected.
###end p 70
###begin title 71
Statistical analysis
###end title 71
###begin p 72
Spearman correlation, Mann Whitney t-tests, and log rank tests were performed as appropriate to test statistical significance using Graphpad Prism v4.2 (Graphpad Software, San Diego, CA). Additional un-paired t-test analysis was performed using JMP statistical software (v7.0) (SAS Institute, Cary, NC).
###end p 72
###begin title 73
Acknowledgments
###end title 73
###begin p 74
We thank the following for advice and technical assistance: Sindy Babinszky, Kristy Dillon, Xiaobo Duan, Sara Hahn, Jodi Leblanc, Heather Lockyer, Michele Martin, Erika Mehl, Jorg Michels, Melanie Olson, Lisa Szegedi, Dr. Nicholas van der Westhuizen, Erika Wall, Laura Walsh, Josh Wang, Nathan West, Taimei Yang and Siao Yong.
###end p 74
###begin title 75
Supporting Information
###end title 75
###begin p 76
(0.15 MB DOC)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
(0.13 MB DOC)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin title 80
References
###end title 80
###begin article-title 81
Standard treatment in advanced ovarian cancer in 2005: the state of the art.
###end article-title 81
###begin article-title 82
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
###end article-title 82
###begin article-title 83
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
###end article-title 83
###begin article-title 84
Ovarian cancer: epidemiology, biology, and prognostic factors.
###end article-title 84
###begin article-title 85
Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.
###end article-title 85
###begin article-title 86
The impact of T-cell immunity on ovarian cancer outcomes.
###end article-title 86
###begin article-title 87
Immune prognostic factors in ovarian cancer: lessons from translational research.
###end article-title 87
###begin article-title 88
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
###end article-title 88
###begin article-title 89
Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma.
###end article-title 89
###begin article-title 90
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
###end article-title 90
###begin article-title 91
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
###end article-title 91
###begin article-title 92
###xml 101 106 <span type="species:ncbi:9606">human</span>
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
###end article-title 92
###begin article-title 93
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3(+)CD56(+) cells with platinum resistance.
###end article-title 93
###begin article-title 94
Interferon-gamma expression is an independent prognostic factor in ovarian cancer.
###end article-title 94
###begin article-title 95
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
###end article-title 95
###begin article-title 96
Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.
###end article-title 96
###begin article-title 97
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma.
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.
###end article-title 98
###begin article-title 99
Class I histocompatibility antigen expression: a prognostic factor for aneuploid ovarian cancers.
###end article-title 99
###begin article-title 100
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
###end article-title 100
###begin article-title 101
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
###end article-title 101
###begin article-title 102
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
###end article-title 102
###begin article-title 103
Anti-tumor antibodies in ovarian cancer.
###end article-title 103
###begin article-title 104
Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q.
###end article-title 104
###begin article-title 105
Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.
###end article-title 105
###begin article-title 106
Autoantibody markers for the diagnosis and prediction of type 1 diabetes.
###end article-title 106
###begin article-title 107
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
###end article-title 107
###begin article-title 108
Delivering the kiss of death: progress on understanding how perforin works.
###end article-title 108
###begin article-title 109
Identification and functional characterization of a TIA-1-related nucleolysin.
###end article-title 109
###begin article-title 110
Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
###end article-title 110
###begin article-title 111
FOXP3: not just for regulatory T cells anymore.
###end article-title 111
###begin article-title 112
Regulatory T cells, tumour immunity and immunotherapy.
###end article-title 112
###begin article-title 113
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
###end article-title 113
###begin article-title 114
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
###end article-title 114
###begin article-title 115
Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.
###end article-title 115
###begin article-title 116
###xml 146 151 <span type="species:ncbi:9606">women</span>
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
###end article-title 116
###begin article-title 117
###xml 26 31 <span type="species:ncbi:9606">human</span>
HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
###end article-title 117
###begin article-title 118
Immunophenotyping of tumor-infiltrating mononuclear cells in ovarian carcinoma.
###end article-title 118
###begin article-title 119
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.
###end article-title 119
###begin article-title 120
###xml 111 117 <span type="species:ncbi:9606">humans</span>
Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans.
###end article-title 120
###begin article-title 121
Substantial proportions of identical beta-chain T-cell receptor transcripts are present in epithelial ovarian carcinoma tumors.
###end article-title 121
###begin article-title 122
Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.
###end article-title 122
###begin article-title 123
T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.
###end article-title 123
###begin article-title 124
TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
###end article-title 124
###begin article-title 125
Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
###end article-title 125
###begin article-title 126
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.
###end article-title 126
###begin article-title 127
Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
###end article-title 127
###begin article-title 128
T-cell recognition of ovarian cancer.
###end article-title 128
###begin article-title 129
HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
###end article-title 129
###begin article-title 130
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
###end article-title 130
###begin article-title 131
###xml 77 82 <span type="species:ncbi:9606">human</span>
Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
###end article-title 131
###begin article-title 132
Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.
###end article-title 132
###begin article-title 133
In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.
###end article-title 133
###begin article-title 134
###xml 33 41 <span type="species:ncbi:9606">patients</span>
P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy.
###end article-title 134
###begin article-title 135
Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.
###end article-title 135
###begin article-title 136
Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
###end article-title 136
###begin article-title 137
Frequency of BRCA1 dysfunction in ovarian cancer.
###end article-title 137
###begin article-title 138
Inactivation of BRCA1 and BRCA2 in ovarian cancer.
###end article-title 138
###begin article-title 139
###xml 115 123 <span type="species:ncbi:9606">patients</span>
T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.
###end article-title 139
###begin article-title 140
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
###end article-title 140
###begin article-title 141
Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells.
###end article-title 141
###begin article-title 142
###xml 51 56 <span type="species:ncbi:9606">human</span>
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
###end article-title 142
###begin article-title 143
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
###end article-title 143
###begin article-title 144
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
###end article-title 144
###begin article-title 145
Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
###end article-title 145
###begin article-title 146
###xml 54 62 <span type="species:ncbi:9606">patients</span>
P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
###end article-title 146
###begin article-title 147
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
###end article-title 147
###begin article-title 148
Th1 and Th2 lymphocytes in autoimmune disease.
###end article-title 148
###begin article-title 149
B cells inhibit induction of T cell-dependent tumor immunity.
###end article-title 149
###begin article-title 150
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
###end article-title 150
###begin article-title 151
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
###end article-title 151
###begin article-title 152
###xml 18 26 <span type="species:ncbi:9606">patients</span>
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.
###end article-title 152
###begin article-title 153
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Cellular immunity in breast cancer patients completing taxane treatment.
###end article-title 153
###begin article-title 154
The immunological effects of taxanes.
###end article-title 154
###begin article-title 155
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
###end article-title 155
###begin article-title 156
Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.
###end article-title 156
###begin article-title 157
###xml 84 89 <span type="species:ncbi:9606">human</span>
Cisplatin at clinically relevant concentrations enhances interleukin-2 synthesis by human primary blood lymphocytes.
###end article-title 157
###begin article-title 158
###xml 131 139 <span type="species:ncbi:9606">patients</span>
Abrogation of suppressor cells activity by cis-diamminedichloroplatinum (CDDP) treatment using therapeutic doses in ovarian cancer patients.
###end article-title 158
###begin article-title 159
Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
###end article-title 159
###begin article-title 160
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
###end article-title 160
###begin article-title 161
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
###end article-title 161
###begin article-title 162
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations.
###end article-title 162
###begin article-title 163
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer.
###end article-title 163
###begin article-title 164
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
###end article-title 164
###begin article-title 165
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
###end article-title 165
###begin article-title 166
Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
###end article-title 166
###begin article-title 167
###xml 183 191 <span type="species:ncbi:9606">patients</span>
Use of a retroviral vector to study the trafficking patterns of purified ovarian tumor infiltrating lymphocytes (TIL) used in intraperitoneal adoptive immunotherapy of ovarian cancer patients. A pilot study.
###end article-title 167
###begin article-title 168
###xml 174 182 <span type="species:ncbi:9606">patients</span>
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
###end article-title 168
###begin article-title 169
A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan.
###end article-title 169
###begin p 170
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 170
###begin p 171
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 45 51 <span type="species:ncbi:9135">Canary</span>
Funding: British Columbia Cancer Foundation, Canary Foundation, U.S. Department of Defense (OC000018). None of the sponsors had any role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
###end p 171

